All stock lists
Unlock the score
X4 Pharmaceuticals, Inc (NASDAQ:XFOR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
3.25+0.01 (+0.31%)
Market cap
$322M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 16, 2017
Website
Insider Score
/ 100
XFOR Insider Score
X4 Pharmaceuticals, Inc has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
Financial Health Score
Weak
From XFOR’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $15.8M
- Net income
- -$90.1M
- Net margin
- -568.8%
Leverage15 / 20
Little or no net debt.
- Total debt
- $77.2M
- Cash
- $195.1M
- Debt / equity
- 0.50
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $218.9M
- Current liabilities
- $19.4M
- Current ratio
- 11.30
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$83.7M
- Free cash flow
- -$83.7M
- FCF margin
- -528.4%
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 126.3M
- Share growth (1y)
- 1604.4%
- Cash runway
- 28 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
XFOR Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 8.81 M | 2.71 M | 2.57 M | 1.76 M | 1.97 M | 28.81 M |
| Revenue Growth (YoY) | 346.33 % | -90.60 % | 79.08 % | 215.18 % | 250.44 % | — |
| Cost of Revenue | 1.62 M | 598.00 K | 387.00 K | 374.00 K | 494.00 K | 5.00 M |
| Gross Profit | 7.19 M | 2.11 M | 2.18 M | 1.39 M | 1.48 M | 23.80 M |
| SG&A Expense | 8.50 M | 6.97 M | 7.38 M | 11.59 M | 9.53 M | 15.02 M |
| R&D Expense | 15.08 M | 15.45 M | 18.50 M | 17.31 M | 18.18 M | 18.22 M |
| Operating Expenses | 23.58 M | 22.42 M | 25.88 M | 28.90 M | 27.71 M | 33.24 M |
| Operating Income | -16.39 M | -20.31 M | -23.70 M | -27.51 M | -26.23 M | -9.44 M |
| Pretax Income | -16.16 M | -20.24 M | -23.93 M | -29.84 M | -25.70 M | 316.00 K |
| Tax Provision | 2.00 K | 0.00 | 0.00 | -30.00 K | 37.00 K | 34.00 K |
| Net Income | -16.16 M | -20.24 M | -23.93 M | -29.82 M | -25.74 M | 282.00 K |
| EPS (Basic) | -0.13 | -0.16 | -0.22 | -0.69 | -3.47 | 0.04 |
| EPS (Diluted) | -0.13 | -0.16 | -0.22 | -0.69 | -3.47 | 0.04 |
| Shares Outstanding | 126.34 M | 126.29 M | 110.56 M | 43.27 M | 7.41 M | 6.84 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.